3 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)
Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet
26
Participants partenaires
TERMINÉ
Profiling Responders In Antibody Therapies (PRIAT)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2014,
"Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$. In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma. However, for most antibody therapies, only a subset of patients benefit from treatment. Thus, there is an ...
Voir le projet
8
Participants partenaires
TERMINÉ
ANTIBODY DERIVATIVES AS MOLECULAR AGENTS FOR NEOPLASTIC TARGETING (ADAMANT)
Date du début: 1 avr. 2008, Date de fin: 31 mars 2011,
"The selective delivery of bioactive agents (cytotoxics, radionuclides, cytokines) at the tumor site, while sparing normal tissues, represents one of the most promising avenues for the development of anticancer therapies with unprecedented efficacy and tolerability. Monoclonal antibodies represent the preferred vehicle for the targeted delivery of bioactive agents to cancer sites, as they can disp ...
Voir le projet